RT Book, Section
T1 Antidepressant and Anticonvulsant Drugs as Adjuvant Analgesics in Chronic Pain
A1 Sebastián-Aldeanueva, Manuel
A1 López-Muñoz, Francisco
A1 Guerra Guirao, José Antonio
A1 Álamo, Cecilio
A2 López-Muñoz, Francisco
A2 Srinivasan, Venkataramanujam
A2 Álamo, Cecilio
A2 Kato, Takahiro A.
AB Adjuvant analgesics are defined as drugs with a primary indication ther than pain that have analgesic properties in some painful conditions. The group includes numerous drugs in diverse classes. Although the widespread use of these drugs as first-line agents in chronic nonmalignant pain syndromes suggests that the term “adjuvant” is a misnomer, they usually are combined with a less-than-satisfactory opioid regimen when administered for cancer pain. Some adjuvant analgesics are useful in several painful conditions and are described as multipurpose adjuvant analgesics (antidepressants, corticosteroids, α2-adrenergic agonists, neuroleptics), whereas others are specific for neuropathic pain (anticonvulsants, local anesthetics, N-methyl-D-aspartate receptor antagonists), bone pain (calcitonin, bisphosphonates, radiopharmaceuticals), musculoskeletal pain (muscle relaxants), or pain from bowel obstruction (octreotide, anticholinergics). This article reviews the evidence supporting the use of two class of adjuvant analgesic for the treatment of chronic pain, antidepressant ans anticonvulsivants, and provides a comprehensive outline of dosing recommendations, side effects, and drug interactions.
PB Springer, New Delhi
SN 978-81-322-2801-1
SN 978-81-322-2803-5
YR 2016
FD 2016-11
LK https://hdl.handle.net/20.500.14352/93920
UL https://hdl.handle.net/20.500.14352/93920
LA eng
NO Sebastián-Aldeanueva, M., López-Muñoz, F., Guerra, J.A., Álamo, C. (2016). Antidepressant and Anticonvulsant Drugs as Adjuvant Analgesics in Chronic Pain. In: López-Muñoz, F., Srinivasan, V., de Berardis, D., Álamo, C., Kato, T. (eds) Melatonin, Neuroprotective Agents and Antidepressant Therapy. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2803-5_33
DS Docta Complutense
RD 9 abr 2025